[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647496":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":53,"collaborators":25,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":25,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":25,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":82,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Shanghai 10th People's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Short peptide group","EXPERIMENTAL","Short peptide EN preparations were administered for nutritional support",[13],"Drug: Short peptide",{"label":15,"type":16,"description":17,"interventionNames":18},"Protein group","ACTIVE_COMPARATOR","Nutritional support therapy was administered with protein type EN preparations",[19],"Drug: Protein",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Short peptide",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Protein","Nutritional support therapy was administered with protein-type EN preparations",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Sheng Wang","CONTACT","+8613641715292","wangsheng@tongji.edu.cn",[37],{"facility":38,"status":25,"city":39,"state":25,"zip":25,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Shanghai Tongji Hospital","Shanghai","China","CN",{"type":43,"coordinates":44},"Point",[45,46],121.45806,31.22222,{"lat":46,"lon":45},[49],{"name":50,"role":33,"phone":51,"phoneExt":25,"email":52},"Huihui Zhu","+8615821646026","huihui01727@163.com",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":57,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Sheng Wang MD PhD","Chief physician","Shanghai Tongji Hospital, Tongji University School of Medicine","100647496","phase-4-a-multicenter-clinical-study-on-protein-absorption-efficiency-in-patients-with-pancreatic-exocrine-insufficiency-in-the-icu-100647496",false,"NCT07709611","A Multicenter Clinical Study on Protein Absorption Efficiency in Patients With Pancreatic Exocrine Insufficiency in the ICU","Comparison of Protein Absorption Efficiency Between Peptide and Whole Protein Enteral Nutrition Preparations in High-risk Groups With Pancreatic Exocrine Insufficiency in the ICU","Inclusion Criteria:\n\n* Age≥ 18 years old, no gender restriction;\n* Meet the criteria for high-risk groups for PEI;\n* AGI≤ Class II, hemodynamically stable, meeting EN initiation criteria;\n* Estimated duration of enteral nutrition support therapy: ≥7 days;\n* The subject or their legally authorized family member must sign the informed consent form\n\nExclusion Criteria:\n\n* Patients who have been clearly diagnosed with PEI or chronic persistent PEI;\n* Patients who have contraindications to enteral nutrition therapy;\n* Patients with severely impaired liver or kidney function;\n* Patients who suffer from amino acid metabolism disorders, severe malnutrition, or cachexia;\n* Patients who have received pancreatic enzyme replacement therapy or taken any medications that may affect protein absorption within 7 days prior to enrollment;\n* Patients for whom the expected length of ICU stay is less than 7 days;\n* Pregnant or lactating women, as well as patients with mental illnesses;\n* Patients who are allergic to any component of the study medication.","ALL","18 Years",{"count":68,"type":69},250,"ESTIMATED","INTERVENTIONAL",[72],"PHASE4","The goal of this clinical trial is to systematically evaluate whether peptide-type enteral nutrition (EN) formulations improve protein uptake efficiency in high-risk groups at ICU PEI, using targeted amino acid metabolomics and gut microbiota co-metabolomics as core quantitative indicators.\n\nResearchers will compare protein absorption efficiency of short-chain peptide and complete protein enteral nutrition formulas in high-risk populations for PEI in the ICU\n\nParticipants will:\n\nEnteral nutrition was administered for ICU critically ill patients with high-risk factors for PEI",[75,76],"High-risk Patients With Pancreatic Exocrine Insufficiency","Enteral Nutrition Feeding",[78,79,80,81],"Pancreatic exocrine Insufficiency","Enteral nutrition","Peptide-based","Absorption efficiency","NOT_YET_RECRUITING","2026-07-13",{"date":85,"type":86},"2026-07-16","ACTUAL",{"date":88,"type":69},"2026-07-01",{"date":90,"type":69},"2027-12-31",{"name":5,"class":6},1]